ESPE Abstracts (2016) 86 P-P1-916

ESPE2016 Poster Presentations Thyroid P1 (48 abstracts)

Papillary Thyroid Carcinoma in a Mother and Child Evolving after the Manifestation of Grave’s Disease

Maryam Al Badi a , Erwin Lankes b , Peter Kuehnen c , Aisha Al Semani a , Heike Biebermann c , Heiko Krude c , Kurt Schmid d & Annette Grueters b


aNational Diabetes and Endocrine Centre, Muscat, Oman; bDepartment of Pediatric Endocrinology, Charité, Berlin, Germany; cInstitute for Experimental Pediatric Endocrinology, Charité University Hospital, Berlin, Germany; dUniversity Hospital, Essen, Germany


Background: Familial PTC manifesting in childhood has been described only in single cases, mainly in the context of rare syndromes (APC-associated-syndrome, PTEN-hamartoma syndromes etc). PTC in Grave’s disease (GD) has been described in adults, but not in familial cases including young children.

Objective and hypotheses: We investigated the association of large metastatic papillary carcinoma (PTC) in a 10 years old female and her mother evolving rapidly in both after the manifestation of Grave’s disease (GD). Our aim was to investigate the genetic basis for the occurrence of non-syndromic familial GD and PTC in an ethnic background with a reported high prevalence of thyroid carcinoma in adults Grave’s disease.

Methods: Genetic analysis of the tumor was performed by targeted array analysis to investigate known mutations to be involved in familial and syndromic PTC. Sequencing of the TSH-receptor gene was performed in DNA obtained from PBC of all living family members (index case, mother, four older siblings without thyroid disorders).

Results: GD was confirmed biochemically in the clinically symptomatic patient. TSH-R Ab were elevated. A 2.1 x 1.3 cm nodule in the right lobe developed 3 months after manifestation of GD and turned out to be a PTC (FNAB and ablative thyroidectomy). GD and subsequent development of a metastatic PTC had been diagnosed in the mother a year preceding the diagnosis in her daughter. Panel sequencing of tumour tissue excluded somatic variants for RAF/11, DDR2 15-18, EGFR 18-21, ERBB2 5,6,15,20,23,29, FGFR1 3,7,13,17,FGFR3, HRAS 2-4,KIT 9-11,13,17,18, KRAS 2-4, MET 3,8,11,14,19, NRAS 2-, PDGFR 12,14,18, PIK3CA 3,5,10,16,21, RET 10,11,13-16, TP53 4-9, APC 1-16, DICER1 1-28, PRKARIA 1-11 and PTEN 1-9 and revealed the PTC-typical BRAF-Mutation (V600E) and 2 described TSH-R variants (c.154C>A?p.Pro52Thr and c.170+63G>C). Segregation of the phenotype with the TSH-R variants in the family could not be demonstrated by Sanger sequencing.

Conclusion: A far undescribed association of familial GD and PTC was not associated with germline variants in the TSH-R gene. NGS (whole exome sequencing of the tumor and PBC derived DNA) will be used to detect the underlying genetic mechanism.

Volume 86

55th Annual ESPE (ESPE 2016)

Paris, France
10 Sep 2016 - 12 Sep 2016

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.